-
Dabrafenib, sold
under the
brand name
Tafinlar among others, is an anti-cancer
medication used for the
treatment of
cancers ****ociated with a
mutated version...
- with the BRAF
inhibitor dabrafenib. As a
result of this research, on 8
January 2014, the FDA
approved the
combination of
dabrafenib and
trametinib for the...
-
study reported that
combining Dabrafenib with a MEK
inhibitor trametinib led to even
better outcomes.
Compared to
Dabrafenib alone, progression-free survival...
-
Hyperkeratosis can also be
caused by B-Raf
inhibitor drugs such as
Vemurafenib and
Dabrafenib. It can be
treated with urea-containing creams,
which dissolve the intercellular...
-
Cancers with
hyperactive BRAF (around 2% of NSCLC) can be
treated by
dabrafenib combined with the MEK
inhibitor trametinib;
those with
activated ROS1...
- pembrolizumab, and nivolumab; BRAF inhibitors, such as
vemurafenib and
dabrafenib; and a MEK
inhibitor trametinib.
Important prognosis factors for nodular...
- LHRH,
Phase II
results for
ovarian cancer. Braf
inhibitors (vemurafenib,
dabrafenib, LGX818) used to
treat metastatic melanoma that
harbors BRAF V600E mutation...
- BRAF
mutations have been developed. Two of
these drugs,
vemurafenib and
dabrafenib, are
approved by FDA for
treatment of late-stage melanoma. Vemurafenib...
-
anaplastic thyroid cancer harboring such mutations. The
combination of
dabrafenib and
trametinib has
shown significant increases in
overall survival and...
- Drug
Trade name Rac
Reference Dabrafenib Tafinlar 0.73
Rosuvastatin Crestor 1.37 in
hemodialysis patients Lisinopril Prinivil and
others 1.38 Ivacaftor...
